Photocure Asa | MedPath

Blue Light Cystoscopy Reveals Hidden Bladder Tumors, Improves Cancer Staging in Major Registry Study

3 months ago

• New data from a 2,854-patient registry study shows Blue Light Cystoscopy detected additional malignant lesions in 7% of cases that were missed by standard white light examination. • The enhanced detection capabilities led to cancer upstaging in 9.3% of cases, potentially altering treatment decisions regarding intravesical therapy and surgical interventions. • The study revealed 335 additional tumors detected only by Blue Light Cystoscopy, with 43% being carcinoma in-situ and 40% representing high-grade tumors.

Hexvix Receives Marketing Approval in China for Bladder Cancer Detection

7 months ago

• Asieris Pharmaceuticals' partner, Jiangsu Yahong Meditech, has received marketing approval from China's National Medical Products Administration (NMPA) for Hexvix. • Hexvix, used with blue light cystoscopy, enhances the detection of bladder cancer, including carcinoma in situ (CIS), leading to more complete surgical resections. • Chinese and international urological associations recommend hexaminolevulinate (HAL), the active ingredient in Hexvix, as the preferred drug for fluorescence cystoscopy. • The commercialization of Hexvix in China is contingent upon the approval of blue light cystoscopes, including Richard Wolf’s System Blue.

Asieris Pharmaceuticals' Cevira (APL-1702) Shows Promise in HSIL Treatment: Phase III Subgroup Analysis

8 months ago

• Asieris Pharmaceuticals presented Phase III trial subgroup analysis of Cevira (APL-1702) at the 2024 CSCO Annual Meeting, focusing on age-related efficacy in treating cervical HSIL. • The study demonstrated a 15-20% increase in pathological regression rate in the 20-40 age group treated with APL-1702 compared to placebo at six months. • APL-1702 showed enhanced HPV clearance rates in the 20-30 age group, indicating its potential to facilitate regression from HSIL to LSIL and clear high-risk HPV infections. • The new drug application for APL-1702 was accepted by the National Medical Products Administration (NMPA) in May 2024.